Microbiome Therapeutic Articles & Analysis
48 news found
It will also use this influx of funds to push forward research of new microbial therapeutics and development of FDA-approved live biotherapeutic products (LBP). Herb Lin, a managing partner at TPTF, first learned of Bened through his fund’s investment in Finch Therapeutics, a microbiome therapy company now listed on the NASDAQ. He ...
Addressing the ‘One Health’ opportunity requires a focus on, and a deep understanding of, microbiome3 and host-microbiome interactions as the common denominator across these domains. ...
About SER-109 SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome. ...
--(BUSINESS WIRE)--May 22, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a ...
--(BUSINESS WIRE)--Mar. 18, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic ...
SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrentC. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the functionality of the microbiome in a rapid and durable manner, which further supports the potential of microbiome ...
--(BUSINESS WIRE)--May 4, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. ...
SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. ...
ByBio-Me
As part of our growth and consolidation as a microbiome company focused on therapeutics we have several openings to join our team! ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s ...
Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome. James discusses how EnteroBiotix is developing its pipeline of highly diverse microbiome enhancing therapeutics through a unique approach to development and manufacturing, focussed on supply chain ...
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. ...
Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). ...
He has been a valued leader at large companies (3M) and emerging startups (Rion, StemoniX, Rebiotix) where he made significant contributions to the pioneering development of regenerative exosome and microbiome therapeutics, 3D organoids for drug discovery, and novel drug delivery technologies. ...
About AB-2004 AB-2004 is a first-in-class, molecular therapeutic that targets the microbiome gut-brain axis and its role in autism. ...
” AB-2004: Novel Small Molecule Therapy with Defined Mechanism of Action AB-2004 is a first-in-class, molecular therapeutic that targets the microbiome gut-brain axis and its role in autism. ...
Stewart Campbell, Ph.D., Chief Executive Officer of Axial Therapeutics. “We are grateful for the support and confidence demonstrated by both our existing and new investors in our novel microbiome approach. ...
This is the most advanced clinical trial of an investigational drug based on a rationally defined bacterial consortium, a microbiome-based therapeutic approach that delivers orally administered candidates of precisely known composition that can be manufactured with pharmaceutical-grade consistency. ...
In addition, the company explains that it is possible to expand indications because therapeutic effects on other autoimmune diseases, such as psoriasis, have been clearly observed. ...